Julia Wypyszyńska

Wstęp: Celem niniejszego badania jest analiza wiedzy zaszczepionych Polaków na temat powikłań po szczepieniu przeciwko COVID-19 w obliczu konieczności zwiększenia wiedzy na temat szczepionek, mechanizmu ich działania oraz powikłań. Materiał i metody: Autorzy stworzyli anonimową ankietę internetową. Badana populacja liczyła 2345 osób, w tym 1468 zaszczepionych przeciwko COVID-19. Wyniki: Jako najczęstsze źródła informacji o szczepionkach wskazywano ulotkę szczepionki, media społecznościowe oraz lekarza. Na pytanie o możliwość zachorowania na COVID-19 w wyniku szczepienia 55,18% respondentów odpowiedziało przecząco. Jedynie 2,72% ankietowanych twierdziło, iż po każdej dawce szczepionki wystąpią powikłania. Zdaniem ankietowanych najczęstszym powikłaniem po szczepionce Comirnaty jest ból mięśni, a po szczepionce Vaxzevria gorączka. W przypadku szczepionek Moderna i Janssen większość nie znała odpowiedzi. Wnioski: Ankietowani wiedzieli najwięcej o powikłaniach mogących wystąpić po przyjęciu szczepionki Comirnaty, a najmniej o powikłaniach po szczepionkach Janssen i Moderna. W przypadku szczepionki Vaxzevria jako jedno z najczęstszych powikłań ankietowani wskazali incydenty zakrzepowo-zatorowe. Najczęstszym źródłem informacji o powikłaniach była ulotka dołączona do szczepionki. Obawy przed powikłaniami deklarowała największa liczba osób zaszczepionych szczepionką Janssen.

Background/Objectives: Lung carcinoma is the leading cause of cancer-related deaths globally, with lung adenocarcinoma being the most prevalent subtype. This study aims to review the clinical data and survival outcomes of patients diagnosed with lung adenocarcinoma who underwent surgical treatment. Methods: We retrospectively analyzed 471 patients (mean age 65.9 ± 7.81 years, range 38–86; 53.5% women) with histopathologically confirmed lung adenocarcinoma who underwent a lobectomy, bilobectomy, or pneumonectomy between May 2012 and December 2022. All patients were followed for up to five years post-surgery. Their medical histories, including previous neoplasms, comorbidities, tumor characteristics, and symptoms, were thoroughly reviewed. We calculated the overall survival rate and evaluated the impact of tumor grading and spread through air spaces (STAS) on patient outcomes. Results: The survival rate for the entire cohort was 76.23%. No significant survival differences emerged between G1 and G2 tumors, whereas both showed markedly better survival rates than G3 tumors. When these findings were applied to a simplified two-tier grading system (low grade vs. high grade), survival analyses showed a clear stratification of prognosis. Patients with STAS had a lower survival rate than those without STAS. Conclusions: Our findings indicate that a simplified grading system may improve prognostic evaluations for lung adenocarcinoma patients. Furthermore, STAS is a crucial factor affecting survival rates and should be considered in future treatment strategies. Expanding research in this area is essential to enhance treatment approaches for lung adenocarcinoma patients.

Background/Objectives: Lung carcinoma is the leading cause of cancer-related deaths globally, with lung adenocarcinoma being the most prevalent subtype. This study aims to review the clinical data and survival outcomes of patients diagnosed with lung adenocarcinoma who underwent surgical treatment. Methods: We conducted a retrospective analysis of 471 patients who had surgery for lung adenocarcinoma at our institution. Their medical histories, including previous neoplasms, comorbidities, tumor characteristics, and symptoms, were thoroughly reviewed. We calculated the overall survival rate and evaluated the impact of tumor grading and spread through air spaces (STAS) on patient outcomes. Results: The survival rate for the entire cohort was 76.23%. There was no significant difference in survival rates between patients classified as G1 and G2, suggesting that a simplified two-tier grading system may be more effective. Patients with STAS had a lower survival rate than those without STAS. Conclusions: Our findings indicate that a simplified grading system may improve prognostic evaluations for lung adenocarcinoma patients. Furthermore, STAS is a crucial factor affecting survival rates and should be considered in future treatment strategies. Expanding research in this area is essential to enhance treatment approaches for lung adenocarcinoma patients.